Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on COSMO Pharmaceuticals N.V., retaining the price target of CHF130.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ram Selvaraju’s rating is based on the promising results from Cosmo Pharmaceuticals’ pivotal Phase 3 trials for Breezula, a novel treatment for male-pattern baldness. The trials demonstrated statistically significant improvements in hair count with a favorable safety profile, marking a potential breakthrough in hair-loss treatment.
The market potential for Breezula is substantial, with an estimated 28 million men globally using hair loss prevention products, representing a potential market size exceeding $20 billion annually. The product’s unique mechanism of action, targeting the root cause of hair loss without systemic absorption, sets it apart from existing therapies. With plans for a telehealth sales channel and long-term safety data expected in 2026, Cosmo aims to launch Breezula in the U.S. by 2027 and in Europe by 2028, supported by patent protection into the 2030s.